source
- Analysts deem AstraZeneca-BMS merger unlikely despite market buzzAnalysts say that talks between AstraZeneca and Bristol Myers Squibb are unlikely to result in a merger because the two companies have overlapping product lines that would attract heavy antitrust s…
- Curium to acquire Lantheus in $8 billion deal, offering $102.5 per share with upside potentialCurium announced it will purchase radiopharmaceutical company Lantheus in a transaction valued at about $8 billion. The agreement sets the purchase price at $102.5 for each Lantheus share, and inc…